If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.

The company has collaboration with Mirador Therapeutics to advance mirador’s precision medicines for immunology and inflammation. 23andMe Holding Co. was founded in 2006 and is headquartered in ...

On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Mark McKenna, CEO of Mirador Therapeutics, a member of ...

The company aims to enter the clinic this year. Mirador Therapeutics is not making immunology and inflammation medicines for today. CEO Mark McKenna wants to be the creator of 2030’s great ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

The FDA decision for Travere Therapeutics’ Filspari also expands its addressable patient population. The full approval comes nearly a year after the Travere drug narrowly missed the main goal of ...

After hours: March 21 at 4:13:35 PM EDT Loading Chart for KPTI ...

After hours: March 21 at 7:05:49 PM EDT Loading Chart for BEAM ...